Literature DB >> 15801950

Sinus zygomycosis in a patient receiving voriconazole prophylaxis.

Michail S Lionakis1, Dimitrios P Kontoyiannis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15801950     DOI： 10.1111/j.1365-2141.2005.05384.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Impact of zygomycosis on microbiology workload: a survey study in Spain.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Patricia Muñoz; Ignacio Gadea; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

Review 3.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

Authors:  Benjamin J Park; Peter G Pappas; Kathleen A Wannemuehler; Barbara D Alexander; Elias J Anaissie; David R Andes; John W Baddley; Janice M Brown; Lisa M Brumble; Alison G Freifeld; Susan Hadley; Loreen Herwaldt; James I Ito; Carol A Kauffman; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Genovefa Papanicolaou; Thomas F Patterson; Trish M Perl; Mindy G Schuster; Randall Walker; John R Wingard; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.